These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
511 related articles for article (PubMed ID: 3734795)
21. SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. II. Biochemical characterization of monoamine oxidase inhibition. Kan JP; Steinberg R; Mouget-Goniot C; Worms P; Bizière K J Pharmacol Exp Ther; 1987 Jan; 240(1):251-8. PubMed ID: 3100771 [TBL] [Abstract][Full Text] [Related]
22. Deamination of norepinephrine, dopamine, and serotonin by type A monoamine oxidase in discrete regions of the rat brain and inhibition by RS-8359. Kumagae Y; Matsui Y; Iwata N Jpn J Pharmacol; 1991 Jan; 55(1):121-8. PubMed ID: 1904113 [TBL] [Abstract][Full Text] [Related]
23. Histochemical characterization of monoamine oxidase in ependyma of rat hypothalamus. Williams D; Gascoigne JE; Street M; Williams ED Histochem J; 1979 Jan; 11(1):83-95. PubMed ID: 429200 [TBL] [Abstract][Full Text] [Related]
24. Increased L-DOPA-derived dopamine following selective MAO-A or -B inhibition in rat striatum depleted of dopaminergic and serotonergic innervation. Sader-Mazbar O; Loboda Y; Rabey MJ; Finberg JP Br J Pharmacol; 2013 Nov; 170(5):999-1013. PubMed ID: 23992249 [TBL] [Abstract][Full Text] [Related]
25. Brain dialysis: in vivo metabolism of dopamine and serotonin by monoamine oxidase A but not B in the striatum of unrestrained rats. Kato T; Dong B; Ishii K; Kinemuchi H J Neurochem; 1986 Apr; 46(4):1277-82. PubMed ID: 2419508 [TBL] [Abstract][Full Text] [Related]
26. The deamination of noradrenaline and 5-hydroxytryptamine by rat brain and heart monoamine oxidase and their inhibition by cimoxatone, toloxatone and MD 770222. Strolin Benedetti M; Boucher T; Fowler CJ Naunyn Schmiedebergs Arch Pharmacol; 1983 Aug; 323(4):315-20. PubMed ID: 6633672 [TBL] [Abstract][Full Text] [Related]
27. Intestinal metabolism of tyramine by both forms of monoamine oxidase in the rat. Benedetti MS; Boucher T; Carlsson A; Fowler CJ Biochem Pharmacol; 1983 Jan; 32(1):47-52. PubMed ID: 6830619 [TBL] [Abstract][Full Text] [Related]
28. Selective inhibition by amiflamine of monoamine oxidase type A in rat brain, liver and duodenum. Ask AL Naunyn Schmiedebergs Arch Pharmacol; 1984 Aug; 327(1):56-63. PubMed ID: 6493351 [TBL] [Abstract][Full Text] [Related]
29. The deamination of dopamine by human brain monoamine oxidase. Specificity for the two enzyme forms in seven brain regions. O'Carroll AM; Fowler CJ; Phillips JP; Tobbia I; Tipton KF Naunyn Schmiedebergs Arch Pharmacol; 1983 Apr; 322(3):198-202. PubMed ID: 6408492 [TBL] [Abstract][Full Text] [Related]
30. Type A monoamine oxidase catalyzes the intraneuronal deamination of dopamine within nigrostriatal, mesolimbic, tuberoinfundibular and tuberohypophyseal neurons in the rat. Demarest KT; Moore KE J Neural Transm; 1981; 52(3):175-87. PubMed ID: 6796650 [TBL] [Abstract][Full Text] [Related]
31. The nature of inhibition of cat brain mitochondrial monoamine oxidase by clorgyline. Youdim MB; Holman B J Neural Transm; 1975; 37(1):11-24. PubMed ID: 1159411 [TBL] [Abstract][Full Text] [Related]
32. Relation between brain monoamine oxidase (MAO) activity and the firing rate of locus coeruleus neurons. Oreland L; Engberg G Naunyn Schmiedebergs Arch Pharmacol; 1986 Jul; 333(3):235-9. PubMed ID: 3762738 [TBL] [Abstract][Full Text] [Related]
33. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo. Lamensdorf I; Youdim MB; Finberg JP J Neurochem; 1996 Oct; 67(4):1532-9. PubMed ID: 8858937 [TBL] [Abstract][Full Text] [Related]
34. Inhibition of monoamine oxidase selectively in brain monoamine nerves using the bioprecursor (E)-beta-fluoromethylene-m-tyrosine (MDL 72394), a substrate for aromatic L-amino acid decarboxylase. Palfreyman MG; McDonald IA; Fozard JR; Mely Y; Sleight AJ; Zreika M; Wagner J; Bey P; Lewis PJ J Neurochem; 1985 Dec; 45(6):1850-60. PubMed ID: 3840523 [TBL] [Abstract][Full Text] [Related]
35. In vitro effects on monoamine uptake and release by the reversible monoamine oxidase-B inhibitors lazabemide and N-(2-aminoethyl)-p-chlorobenzamide: a comparison with L-deprenyl. Bondiolotti GP; Galva MD; Villa F; Sciaba L; Picotti GB Biochem Pharmacol; 1995 Jun; 50(1):97-102. PubMed ID: 7605351 [TBL] [Abstract][Full Text] [Related]
36. (-)-Trans-epsilon-viniferin, a polyphenol present in wines, is an inhibitor of noradrenaline and 5-hydroxytryptamine uptake and of monoamine oxidase activity. Yáñez M; Fraiz N; Cano E; Orallo F Eur J Pharmacol; 2006 Aug; 542(1-3):54-60. PubMed ID: 16828740 [TBL] [Abstract][Full Text] [Related]
37. The metabolism of dopamine by both forms of monoamine oxidase in the rat brain and its inhibition by cimoxatone. Fowler CJ; Benedetti MS J Neurochem; 1983 Jun; 40(6):1534-41. PubMed ID: 6406646 [TBL] [Abstract][Full Text] [Related]
38. Monoamine oxidase-inhibiting properties of SR 95191, a new pyridazine derivative, in the rat: evidence for selective and reversible inhibition of monoamine oxidase type A in vivo but not in vitro. Kan JP; Steinberg R; Leclercq J; Worms P; Biziere K J Neurochem; 1988 Apr; 50(4):1137-44. PubMed ID: 3346672 [TBL] [Abstract][Full Text] [Related]
39. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl. Riederer P; Youdim MB J Neurochem; 1986 May; 46(5):1359-65. PubMed ID: 2420928 [TBL] [Abstract][Full Text] [Related]